Glucotrack, Inc.

Glucotrack, Inc. is a medical device company incorporated on May 18, 2010, in Delaware. The company is focused on developing the Glucotrack CBGM, an implantable continuous blood glucose monitor for individuals with Type 1 diabetes and Type 2 diabetes who use insulin or are at risk for hypoglycemia. Initially, Glucotrack was founded to develop Glucotrack®, a non-invasive glucose monitoring device that obtained readings via a small sensor clipped onto the earlobe. This first-generation product received CE Mark approval and underwent a limited release beta test in Europe and the Middle East. However, in 2023, the company shifted its focus to continuous measurement devices, withdrawing the CE Mark for the original Glucotrack and discontinuing its commercialization and further development. On October 7, 2022, Glucotrack acquired intellectual property related to the Glucotrack CBGM from Paul V. Goode, the company's Chief Executive Officer. The company is currently developing the Glucotrack CBGM for Type 1 diabetes patients and Type 2 diabetes patients using insulin or at risk for hypoglycemia. Key to this device's success is implant longevity. The company's sensor chemistry has evolved, with an in-vitro feasibility study demonstrating a minimum two-year implant life is highly probable with the current sensor design. Subsequently, the company announced that a 3-year longevity is feasible based on both in-vitro and in-silico test results.